|
MARK3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11022302462516E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62503344114384E-12 |
| Normal-vs-Stage2 |
5.803200E-04 |
| Normal-vs-Stage3 |
1.27675647831893E-14 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
2.186300E-02 |
| Stage1-vs-Stage3 |
1.021440E-01 |
| Stage1-vs-Stage4 |
9.004000E-03 |
| Stage2-vs-Stage3 |
4.919100E-03 |
| Stage2-vs-Stage4 |
1.762900E-04 |
| Stage3-vs-Stage4 |
2.391600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.201500E-04 |
| Normal-vs-Asian |
1.63946634046397E-12 |
| Caucasian-vs-AfricanAmerican |
3.153000E-01 |
| Caucasian-vs-Asian |
9.544600E-01 |
| AfricanAmerican-vs-Asian |
3.192600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.50509604779359E-11 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
1.653220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
4.77395900588817E-15 |
| Normal-vs-Age(61-80Yrs) |
8.06269495612355E-11 |
| Normal-vs-Age(81-100Yrs) |
5.661700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.301600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.803200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.290000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.204800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.602400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.736000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.52849999324189E-09 |
| Classical-VS-Follicular |
1.588080E-04 |
| Classical-VS-Other |
9.033600E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
4.48419079646101E-13 |
| Tall-VS-Other |
8.157900E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.983010E-01 |
| Follicular-VS-Normal |
2.240000E-03 |
| Other-VS-Normal |
1.421480E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22777352121284E-12 |
| Normal-vs-N1 |
1.62858615482264E-12 |
| N0-vs-N1 |
2.237900E-03 |
|
|
